MarketFriction

Gufic BioSciences Ltd

NSE GUFICBIO · BSE 509079 · Pharmaceuticals
₹418.40 -3.15%
NSE close2026-10-01
52 week range268.00 - 467.80
Market cap₹4,377 Cr.
P/E59.5
Price band 20% Delivery 41.5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales215202195203204208205227230231252261
Expenses176165161167166174178195195195206214
Operating Profit393634363934273236364647
OPM %18%18%18%18%19%16%13%14%16%16%18%18%
Other Income0011020121-10
Interest4345558910899
Depreciation444445888888
Profit before tax313027282926111621212830
Tax %25%25%26%26%26%26%26%26%27%26%26%26%
Net Profit23222021221981215162122
EPS in Rs2.392.222.002.082.171.930.791.201.491.552.052.24
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales201245306351379488779691807820940974
Expenses181222267305327404631556657683790810
Operating Profit202339465284148135150136150165
OPM %10%9%13%13%14%17%19%20%19%17%16%17%
Other Income11446433-0432
Interest6691014145817253737
Depreciation44451416192217213131
Profit before tax101430353058127107116948599
Tax %29%37%45%38%25%23%24%25%26%26%26%
Net Profit7916222344968086706374
EPS in Rs0.951.172.132.822.925.689.898.228.596.976.307.33
Dividend Payout %5%4%2%2%2%2%1%1%1%1%2%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth17%14%11%15%
Compounded Profit Growth24%7%-7%20%
Stock Price CAGR28%18%15%23%
Return on Equity20%18%13%10%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital8888810101010101010
Reserves1926304668120164259338523591654
Borrowings33435780981266264334333336405
Other Liabilities677584104106152157188179227232273
Total Liabilities1271521782382804083925218611,0931,1701,342
Fixed Assets252222232483100115160159506491
CWIP-0-002103113411703072222
Investments000000001233
Other Assets102130156213245294279365531625639826
Total Assets1271521782382804083925218611,0931,1701,342
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity11-4-4-554787106-27-712344
Cash from Investing Activity-2-1-5-9-13-43-7-95-191-102-72-31
Cash from Financing Activity-557148-4-79-623482-3732
Net Cash Flow4-0-11-002517-271445
Free Cash Flow9-5-8-13-877519-214-1165213
CFO/OP92%-8%2%30%33%110%115%94%1%13%107%37%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days8210278971071039371109149140115
Inventory Days165180190238190249138102202188211281
Days Payable223188132192157238162125143156155173
Cash Conversion Cycle25941361431411146948167181197224
Working Capital Days41814264017635068979381
ROCE %18%24%24%33%30%21%29%46%23%17%13%12%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters75.00%72.51%72.51%72.51%72.51%72.51%72.51%72.51%72.50%72.50%72.50%72.50%
FIIs0.72%0.47%0.12%0.23%0.23%0.30%0.31%0.32%0.33%0.44%0.42%0.47%
DIIs1.63%1.72%2.20%2.38%2.51%2.99%3.39%3.38%3.66%3.74%3.83%3.67%
Public22.64%25.29%25.17%24.89%24.75%24.20%23.79%23.81%23.51%23.30%23.23%23.36%
No. of Shareholders36,55734,42434,69532,25032,82533,29931,84431,87631,42030,36229,22329,753

Fundamentals

Market Cap₹ 4,377 Cr.
Current Price₹ 436
Stock P/E59.5
Book Value₹ 66.2
ROCE12.2 %
ROE9.98 %
Dividend Yield0.02 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)15%
Compounded Profit Growth (TTM)20%
Standalone figures.
Valuation
Market capRs 4,196 Cr
Enterprise valueRs 4,526 Cr
P/E (TTM)57.06x
Price to book6.32x
Price to sales4.31x
EV / EBITDA27.12x
EV / EBIT33.26x
EV / sales4.65x
Price to cash flow94.95x
Earnings yield1.75%
Dividend yield0.02%
P/E, 3-year average41.53x
P/B, 3-year average5.02x
P/E, 5-year average34.49x
P/B, 5-year average5.85x
Profitability
Operating margin (excl. other income)15.99%
Operating margin (incl. other income)16.26%
EBITDA margin17.13%
Pre-tax margin10.20%
Net profit margin7.55%
Net margin, latest quarter8.61%
ROE9.98%
ROCE12.17%
ROA5.03%
ROE, 3-year average13.96%
ROCE, 3-year average14.16%
ROA, 3-year average6.68%
ROE, 5-year average22.21%
ROCE, 5-year average22.33%
ROA, 5-year average10.51%
ROIC (approx.)10.11%
Tax rate26.12%
Other income / net worth0.39%
Growth
Sales growth (latest year)14.72%
Profit growth (latest year)-9.70%
Sales CAGR, 3 years10.84%
Sales CAGR, 5 years14.04%
Profit CAGR, 3 years-7.47%
Profit CAGR, 5 years7.38%
Sales growth QoQ3.48%
Profit growth QoQ9.19%
Sales growth YoY (latest quarter)14.94%
Profit growth YoY (latest quarter)86.08%
Per share
EPS (TTM)Rs 7.33
EPS (latest year)Rs 6.30
EPS (latest quarter)Rs 2.24
EPS, 3-year averageRs 7.29
EPS, 5-year averageRs 7.99
Book value per shareRs 66.23
Sales per shareRs 97.16
Cash flow per shareRs 4.41
Free cash flow per shareRs 1.30
Dividend per share (latest year)Rs 0.10
Dividend per share, 3-year averageRs 0.10
Dividend per share, 5-year averageRs 0.10
Dividends
Dividend payout1.58%
Dividend payout, 3-year average1.39%
Dividend payout, 5-year average1.28%
Efficiency
Asset turnover0.70x
Fixed asset turnover1.92x
Inventory turnover1.54x
Inventory days237 days
Debtor days115 days
Debtors turnover3.16x
Creditor days173 days
Cash conversion cycle224 days
Working capital days81 days
Leverage
Total debtRs 405 Cr
Cash and bankRs 74 Cr
Net debtRs 330 Cr
Debt to equity0.61x
Net debt / EBITDA1.98x
Interest coverage3.71x
Current ratio (filing 2026-03-31)1.55x
Quick ratio (filing 2026-03-31)0.92x
Trade payables (filing 2026-03-31)Rs 199 Cr
Owners' fund to total sources49.51%
Debt to assets30.17%
Cash flow
Cash from Operating Activity (latest year)Rs 44 Cr
Cash from Investing Activity (latest year)Rs -31 Cr
Cash from Financing Activity (latest year)Rs 32 Cr
Net Cash Flow (latest year)Rs 45 Cr
Free cash flow (latest year)Rs 13 Cr
FCFE (approx.: FCF + change in debt)Rs 82 Cr
Cash from ops / profit, 5 years0.61x
Sales to cash flow21.28x
Statement figures
Net sales (TTM)Rs 974 Cr
Net sales (latest year)Rs 940 Cr
Sales (latest quarter)Rs 261 Cr
Operating profit excl. other income (latest year)Rs 150 Cr
Operating profit (latest quarter)Rs 47 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 167 Cr
PBDT (TTM)Rs 130 Cr
Profit before tax (TTM)Rs 99 Cr
Tax (latest year)Rs 22 Cr
Net profit (TTM)Rs 74 Cr
Net profit (latest year)Rs 63 Cr
Net profit (latest quarter)Rs 22 Cr
Depreciation (TTM)Rs 31 Cr
Depreciation (latest quarter)Rs 8 Cr
Interest (TTM)Rs 37 Cr
Cost of goods sold (latest year)Rs 499 Cr
Total expenditure (latest year)Rs 790 Cr
Total income (latest year)Rs 943 Cr
Share capitalRs 10 Cr
ReservesRs 654 Cr
Shareholders' fundsRs 664 Cr
Total assetsRs 1,342 Cr
Net blockRs 491 Cr
Capital work in progressRs 22 Cr
InvestmentsRs 3 Cr
ReceivablesRs 297 Cr
InventoryRs 324 Cr
Other liabilitiesRs 273 Cr
Shares outstanding (crore)10.03
Ownership
Promoter holding72.50% (-0.01 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 57.1 is at the 75th percentile of its own 9.4-year range (median 46.8, low 19.5, high 157.5).
P/B 6.32 is at the 14th percentile (median 8.57).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodGUFICBIONifty 50Difference
1 week-0.9%-2.8% +1.9 pts
1 month-0.6%-6.8% +6.2 pts
3 months+7.3%-7.6% +14.9 pts
6 months+52.8%+0.4% +52.4 pts
1 year+15.7%-9.9% +25.6 pts
2 years+4.5%-13.6% +18.0 pts
3 years+45.8%+14.2% +31.7 pts
5 years+117.1%+27.9% +89.2 pts
12 mutual fund schemes hold about ₹182 Cr. Over three months 2 bought more and 8 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
ICICI Pru Multi Cap Fund0.32%62 -11%
ICICI Pru Multi Cap Fund0.32%59 -11%
Bank of India Small Cap Fund0.72%24 -26%
SBI Healthcare Opp Fund0.29%17 -34%
Bank of India Mfg & Infra Fund(Q1.11%11 +7%
Bank of India Business Cycle Fund1.32%6 -5%
ICICI Pru ELSS-Tax Saver Fund0.03%4 -17%
Bank of India Midcap Tax Fund-Sr 20.99%0 +100%
Bandhan BSE Healthcare Index Fund0.07%0 -9%
ICICI Pru Small Cap Fund0.00%0 -100%
ICICI Pru Small Cap Fund0.00%0 -100%
Motilal Oswal BSE 1000 Index Fund0.01%0

Red flags

F-score 4 of 8
lookInventory outrunning sales Inventory grew 50% vs sales +15% in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹261 Cr +15.0% vs Jun 2025. Net profit ₹22 Cr +83.3%.
Against our estimate for Jun 2026: sales -1.7%, profit +23.2% beat. Our estimate for Sep 2026: sales Rs 274 Cr, profit Rs 21 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-08-28Dividend - Re 0.10 Per Share
2025-09-22Dividend - Re 0.10 Per Share
2024-09-17Annual General Meetingdividend - Re 0.10 Per Share
2023-09-21Annual General Meeting/Dividend - Re 0.10 Per Share
2022-08-24Annual General Meeting/Dividend - Rs 0.10 Per Sh
2021-09-09 Annual General Meeting/Dividend - Rs 0.10 Per Share
2020-11-03 Annual General Meeting/Dividend - Rs 0.05 Per Share
2019-09-20 Annual General Meeting/Dividend - Rs 0.05 Per Equity Share
2018-09-19 Annual General Meeting/Dividend Re 0.05 Per Share
2017-08-28 Annual General Meeting/Dividend - Re 0.05 Per Share
2016-09-19 Annual General Meeting/Dividend - Re 0.05 Per Share
2015-09-22 Annual General Meeting/ Dividend - Re 0.05/- Per Share
2014-09-18Annual General Meeting / Final Dividend - Re 0.05/- Per Share
2013-09-19Annual General Meeting / Dividend - Re 0.05/- Per Share (Bc Dates Revised)
2012-08-16Annual General Meeting/ Dividend Rs. 0.05 Per Share
2011-09-16Annual General Meeting And Dividend Re.0.05 Per Share
2010-09-20Annual General Meeting And Dividend Re.0.05 Per Share
2009-09-17Agm/Div-Re.0.05 Per Share
2008-12-11Agm/Dividend - 5%
2008-03-19Agm/Dividend - 5%
2006-09-20Agm/Div-Rs.0.16/- Per Sh
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2020-12-03NCLTGufic Biosciences Limited Vs N/A
2020-11-26NCLTGufic Biosciences Limited Vs N/A
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Scrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Gufic BioSciences Ltd?

Gufic BioSciences Ltd (GUFICBIO) has a market capitalisation of Rs 4,377 Cr. at the 2026-10-01 close.

What is the P/E ratio of Gufic BioSciences Ltd?

Gufic BioSciences Ltd trades at a P/E of 59.5 on trailing twelve-month profit, at the 2026-10-01 close.

What were Gufic BioSciences Ltd's latest quarterly results?

In the Jun 2026 quarter, Gufic BioSciences Ltd sales was Rs 261 Cr (+15.0% vs Jun 2025) and net profit was Rs 22 Cr.

What is the 52-week high and low of Gufic BioSciences Ltd?

The 52-week high is Rs 467.80 and the 52-week low is Rs 268.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03